Kanion Pharmaceutical To Set Up Production Facility In Zhongshan
This article was originally published in PharmAsia News
Kanion Pharmaceutical Co. Ltd. has signed an agreement with Zhongshan city in Guangdong province to set up an anti-tumor drug production base and R&D center. It has committed an initial investment of 280 million yuan. The annual production value is projected to reach 2 billion yuan when the facility is in full operation. The Modern Chinese Medicine Park of South China promises to provide support in terms of land, location, R&D, tax relief, registration and other industry services. Kanion is a top-50 TCM enterprise and its key product, Guizhi Fuling soft gel capsule, has received approval for a Phase II clinical trial in the U.S. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.